Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia

India, June 2 -- Reviva Pharmaceuticals Holdings, Inc. (RVPH) Monday announced a positive full dataset following the completion of its Phase 3 RECOVER open-label extension (OLE) 1-year study evaluating the long-term safety, tolerability and efficacy of brilaroxazine in patients with schizophrenia. Results from the study showed that treatment with brilaroxazine led to strong broad-spectrum efficacy lasting more than 1 year and was generally well tolerated with a 35% discontinuation rate.

Long-term safety data from 100 patients who completed one year of treatment is required to submit NDA for brilaroxacin to the US Food and Drug Administration (FDA).

For comments and feedback contact: [e-mail]

Published by HT Digital Content S...